...
首页> 外文期刊>Cancer Management and Research >Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child–Pugh I who underwent curative resection: a prognostic nomogram study
【24h】

Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child–Pugh I who underwent curative resection: a prognostic nomogram study

机译:乳酸脱氢酶/白蛋白比对Child–Pugh I肝癌患者行根治性切除术的预后影响:诺模图研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Radical resection is the treatment of choice for hepatocellular carcinoma (HCC). However, even with this treatment, HCC prognosis and the efficacy of current predictive models for such patients remain unsatisfactory. Here, we describe an accurate and easy-to-use prognostic index for patients with HCC who have undergone curative resection. Methods: The study population comprised of 1,041 patients with HCC who underwent curative?resection at Zhongshan Hospital. This population was reduced to 768 patients who were treated in 2012 analyzed as the training cohort and 273 patients treated in 2007 who were used as a validation cohort. Results: The lactic dehydrogenase to albumin ratio (LAR) was identified as a significant prognostic index for both overall survival and recurrence-free survival in two independent cohorts. The optimal cutoff value for LAR was determined to be 5.5. The C-index of LAR was superior to other inflammatory scores and serum parameters. This biomarker was also shown to be a stable predictive index in the validation cohort. The new nomogram combining LAR with the Barcelona Clinic Liver Cancer staging system had an improved ability to discriminate overall survival and recurrence-free survival. Nomogram predictions were consistent with observations based on calibration and decisive curve analysis in both independent cohorts. Conclusion: LAR is a novel, convenient, reliable, and accurate prognostic predictor in patients with HCC undergoing curative resection. Our results suggest the recommendation of LAR to be used in routine clinical practice.
机译:背景:根治性切除术是肝细胞癌(HCC)的首选治疗方法。但是,即使采用这种治疗方法,对于此类患者的HCC预后和当前预测模型的效果仍不能令人满意。在这里,我们为经过根治性切除的HCC患者描述了一种准确且易于使用的预后指标。方法:研究人群包括中山医院接受根治性切除术的1,041例HCC患者。将该人群减少为768位患者,这些患者在2012年作为训练队列进行了分析,在273位患者在2007年作为验证队列进行了分析。结果:乳酸脱氢酶与白蛋白之比(LAR)被确定为两个独立队列的总体生存率和无复发生存率的重要预后指标。确定LAR的最佳截止值为5.5。 LAR的C指数优于其他炎症评分和血清指标。该生物标志物在验证队列中也显示为稳定的预测指标。结合LAR和巴塞罗那临床肝癌分期系统的新列线图具有更好的辨别总体生存率和无复发生存率的能力。两项独立队列中的线型图预测与基于校准和决定性曲线分析的观察结果一致。结论:LAR是一种治愈性肝癌患者的新颖,方便,可靠,准确的预后指标。我们的结果表明,LAR推荐用于常规临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号